Zogenix, Inc. (NASDAQ:ZGNX) is scheduled to be posting its quarterly earnings results after the market closes on Tuesday, August 8th. Analysts expect Zogenix to post earnings of ($0.89) per share for the quarter.
Zogenix (NASDAQ:ZGNX) last announced its quarterly earnings results on Thursday, May 4th. The company reported ($0.85) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.88) by $0.03. Zogenix had a negative return on equity of 57.74% and a negative net margin of 360.89%. The firm had revenue of $2.70 million during the quarter, compared to analyst estimates of $4.23 million. During the same quarter in the previous year, the business earned ($0.42) EPS. Zogenix’s revenue for the quarter was down 70.7% compared to the same quarter last year. On average, analysts expect Zogenix to post $-3.63 EPS for the current fiscal year and $-3.04 EPS for the next fiscal year.
Shares of Zogenix, Inc. (NASDAQ ZGNX) traded up 1.20% during trading on Thursday, hitting $12.60. The company had a trading volume of 213,471 shares. The stock’s 50-day moving average is $14.08 and its 200 day moving average is $11.66. The firm’s market capitalization is $312.66 million. Zogenix, Inc. has a 52-week low of $7.50 and a 52-week high of $15.40.
A number of research analysts have issued reports on the stock. Zacks Investment Research cut shares of Zogenix from a “buy” rating to a “hold” rating in a report on Thursday. BidaskClub cut shares of Zogenix from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $26.00 price objective on shares of Zogenix in a research note on Monday, June 26th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $23.00.
In related news, major shareholder Life Sciences Maste Perceptive purchased 175,653 shares of the firm’s stock in a transaction on Friday, June 30th. The shares were bought at an average price of $14.45 per share, for a total transaction of $2,538,185.85. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.00% of the stock is currently owned by company insiders.
About Zogenix
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
